Skip to main content
Premium Trial:

Request an Annual Quote

AltheaDx Closes $30M Series C Financing Round

NEW YORK (GenomeWeb) – Pharmacogenomic testing firm AltheaDx today announced it has raised $30 million in Series C financing.

WuXi Healthcare Ventures led the round, joined by WuXi PharmaTech, Ally Bridge Group, and Alma Life Sciences.

AltheaDx said it would use the funds for prospective trials for its IDgenetix test portfolio, product enhancements, and other growth opportunities.

The firm's IDgenetix tests incorporate a patient's relevant drug metabolism-related genetic markers, among other factors, to identify appropriate therapies. "This investment allows the company to position IDgenetix as a leading clinically relevant tool in therapeutic decision making," AltheaDx CEO Greg Hamilton said in a statement.

AltheaDx has pharmacogenomic tests for cardiovascular, psychiatric, and thrombophilia-related disorders. The firm has a CAP-accredited and CLIA-certified laboratory in San Diego, where it is based.

The funding comes several months after AltheaDx backed away from a $74.3 million proposed initial public offering. It proposed the IPO in January, but withdrew it in March.


The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.